Instagram Ern-EyeFacebook Ern-EyeTwitter Ern-EyeLinkedIn Ern-EyeYouTube Ern-EyeHow to use the speech recognition tool?
NCT01736592
A Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt’s Macular Degeneration
A Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt’s Macular Degeneration.
Type: Interventional
Status of the trial: Active, Not recruiting
Orphan Drug Recognition: NA
Inclusion
- Opening Date: 2014-01-01
- Closing Date: 2029-01-01
Criteria
Inclusion: Patient must have received a subretinal injection of SAR422459. Patient must have completed protocol TDU13583 to Week 48 or undergone an early discontinuation visit.
Exclusion: Patient did not receive SAR422459 as part of the TDU13583 protocol
Children: No
Adults: Yes
Funder Type: industry
HCP: Principal investigators
HCP: Other investigators
Within ERN-EYE members
Workgroups
Retinal Rare Eye Diseases (WG1)
This ERN is supported by:
